Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025.

Lewis is a proven global healthcare leader with a track record of utilizing technology to drive both cultural and ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which ...

The live presentations will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website ...

SAN DIEGO, Nov. 5, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at three upcoming investor conferences in November. The live presentations will be webcast and ...

SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5 ...

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to ...